not used title
not used title
The U.S. Food and Drug Administration (FDA) approved a total of 60 new drugs in 2021. A new report from the FDA catalogs 50 new approvals by the Center for Drug Evaluation and Research (CDER). Separately, the Center for Biologics Evaluation and Research (CBER) approved 10. These novel medicines offer to transform many debilitating diseases, resulting in improved survival, better health outcomes, enhanced quality of life — and in many cases, they provide a first-time treatment option for patients.
According to the CDER report, 54% (27) of the novel medicines approved last year were first-in-class, providing new options of treating diseases — such as a new treatment for the most common type of lupus as well as another medicine for a serious complication of lupus affecting the kidneys: lupus nephritis. New first-in-class treatments also include new medicines for lung cancer as well as new medicines to treat a common and deadly virus in post-transplant patients. Additional novel approvals last year include medicines to reduce risk of cardiovascular death and heart failure hospitalization, to treat a genetic form of endometrial cancer, to address episodic migraines and the first complete HIV treatment that can be administered once a month.
While the number of medicines approved by the FDA ebbs and flows annually, the significant number of approvals occurring during the pandemic is a testament to the Agency's commitment to the public health and the dedication of biopharmaceutical researchers to drive medical advancements despite the ongoing challenges of COVID-19.
At CBER, five new approved vaccines, including the first FDA-approved COVID-19 occurred in 2021, as well as two new CAR-T cell therapies for certain types of multiple myeloma and lymphoma. CAR-T cell therapies represent a game-changing approach involving permanently altering a patient’s T-cells to recognize, target and kill cancer cells.
Key takeaways from the new CDER report include:
The FDA User Fee Program is Working
The PDUFA program helped speed access to therapies for patients with severe asthma and lupus, among other diseases. Additionally, 38 out of 50 (76%) of the newly approved medicines were approved in the United States before any other country.
Among the novel medicines approved this past year, 37 of them (74%) used one or more expedited programs, and 14 (28%) of them were put through the accelerated approval pathway. Accelerated approval allows for earlier approval, based on a surrogate or intermediate clinical endpoint, of drugs that treat serious conditions and that fill an unmet medical need, all while preserving FDA’s high standards for safety. The pathway has been critical to allowing earlier access to important treatment advances for patients across diseases, especially cancer.
These examples illustrate PDUFA’s effectiveness in helping FDA to fulfill its central mission — to protect and advance the public health — by allowing the Agency to stay abreast of ever-evolving science and have the resources to keep pace with the innovative drugs and biologics entering the review pipeline.
New Uses of Approved Medicines and Expanded Medicine Approval for Pediatric Populations
Continual research and development, even after a medicine has already been approved by the FDA, often results in new uses for a medication, including for treatment earlier in a disease, for different patient populations such as a pediatric population, or for entirely different diseases or conditions. Medical advances that happen after initial FDA approval have resulted in improved survival rates, better quality of life and facilitated improved ease of use leading to enhanced patient outcomes. In 2021 alone, several medicines were approved for uses beyond their original FDA approval including treatments for many different types of cancers, as well as many rare and chronic diseases.
Inclusion of pediatric information in the labeling for many medicines often require additional pediatric-specific studies and the submission of new data to support the safe and effective use of the medicine in pediatric patients. These studies and expanded labeling are critical to providing new treatment options for pediatric populations. For example, a medicine that was originally approved in 2010 for adults with a certain type of irregular heartbeat was approved in 2021 for use to prevent and treat blood clots in patients as young as 8 years old — providing the first oral blood thinning medication for children. Additional approvals in 2021 specifically for pediatric populations include medicines to treat children with sickle cell disease, HIV, hepatitis C, cystic fibrosis, high risk cardiovascular conditions and many more.
Continued Progress for Rare Diseases
Of CDER’s approvals last year, 26 of the 50 medicines (52%) were approved to treat rare or “orphan” diseases. Rare or “orphan” diseases are diseases that affect less than 200,000 people in the U.S. These include treatments for many devastating and life-threatening genetic disorders as well as many rare forms of cancer — including for example:
- A medicine to treat patients one year and older with late-onset Pompe disease, a disease that causes muscle weakness and premature death from respiratory or heart failure.
- A medicine to reduce risk of death due to molybdenum cofactor deficiency type A, which presents in the first few days of life, causing seizures, brain injury and death.
- Medicines to treat rare blood disorders and diseases leading to liver dysfunction and failure.
- Medicine to treat certain types of lung cancer, leukemia and lymphoma.
As we look to the future, biopharmaceutical companies are committed to continuing to research and develop treatments that improve the lives of patients. Furthermore, new developments in medical and fundamental science — including immunotherapies and cell and gene therapies — hold the promise of treating debilitating diseases such as cancer, diabetes and many rare disorders. Fulfilling this promise depends on continuing to modernize the drug development and regulatory framework that PDUFA helps facilitate. In turn, this allows FDA to better serve patients by providing timely, science-based regulatory decisions. It is critical that Congress reauthorizes the PDUFA program before its expiration in September 2022.
To learn more about last year’s advancements from the CDER New Drug Therapy Approvals 2021 report click here.
Richard Moscicki M D
Dr. Moscicki served as executive vice president, Science and Regulatory Advocacy and chief medical officer at PhRMA from 2017-summer of 2022. He joined the organization after serving as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) since 2013. While at FDA, Dr. Moscicki brought executive direction of Center operations and leadership in overseeing the development, implementation, and direction of CDER’s programs. Previous positions include serving as Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs for the company. He served as the senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013.
Richard Moscicki M D
Why PDUFA VIII keeps patients first and strengthens America's biopharma leadership
September 15, 2026
Bayh-Dole: The fuel for America’s innovation engine
September 2, 2026
ICYMI: Biopharmaceutical companies in America hit new investment milestone
August 14, 2026
Mass compounding puts patients at risk
July 16, 2026
World Sickle Cell Day: Recognizing the promise of gene therapy
June 19, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
PDUFA creates an efficient drug review process that benefits American patients
April 22, 2026
How AI is transforming the drug innovation lifecycle
March 19, 2026
Advancing patient care: A look at new medicines approved in 2025
January 30, 2026
Knockoffs of FDA-approved drugs put patients at risk
December 1, 2025
PDUFA: Essential to America’s edge in drug development and patient access
October 31, 2025
What to know about vaccine ingredients: Aluminum and thimerosal
June 24, 2025
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
June 17, 2025
PhRMA Foundation celebrates 60 years of investing in future scientific leaders
June 11, 2025
New report: Post-approval innovation delivers substantial patient benefits
June 2, 2025
ICYMI: PhRMA submits comments to White House on artificial intelligence
March 17, 2025
4 things to know on Rare Disease Day
February 28, 2025
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
February 21, 2025
New policy agenda charts solutions for a healthier America
February 20, 2025
A successful PhRMA Forum highlights our commitment to a healthier America
February 20, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Major drug compounder is spending millions on misleading Super Bowl ad
February 5, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
A new administration poses new opportunities for patient access
December 17, 2024
Congratulations to our 2024 Working for Cures Employee Champions
December 11, 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
New Report: Tackling chronic conditions with preventive treatment
September 30, 2024
Addressing the mounting threat of antimicrobial resistance
September 23, 2024
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
September 19, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
How to protect your children’s health this school year
August 22, 2024
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
August 1, 2024
More oversight needed of unapproved medicines that threaten patients’ health
August 1, 2024
Three things to know about the United Nations’ new HIV/AIDS report
July 31, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
June 27, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eisai
June 24, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
June 20, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
Women’s Health Month: A conversation with Astellas
May 31, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
Women’s Health Month: A conversation with Sage
May 23, 2024
The use of real-world data in drug development
May 13, 2024
New analysis: Accelerated approval pathway is changing lives in underserved communities
April 30, 2024
World Vaccine Congress: Building on vaccine success
April 1, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
What new cures would mean to families
March 7, 2024
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
February 29, 2024
American Heart Month: A nurse’s perspective
February 27, 2024
Proposed march-in framework would chill American innovation
February 7, 2024
Three things to know about antibody drug conjugates
February 2, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
What they are saying: Experts agree that proposed march-in framework would jeopardize innovation
January 25, 2024
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
January 23, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
Florida’s importation plan puts patients in danger
January 5, 2024
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
December 19, 2023
The White House continues to attack American innovation
December 15, 2023
Taking stock of obesity and its costly effects
December 8, 2023
Congratulations to our 2023 Working for Cures Employee Champions
December 6, 2023
Watch: Putting patients front and center for World AIDS Day
November 30, 2023
Misuse of march-in could stifle innovation
November 27, 2023
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
Don't close the door on rare disease research
November 13, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
Word of the Month: The Bayh-Dole Act
November 8, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
Three things economists are saying about the Inflation Reduction Act
October 11, 2023
Celebrating Hispanic Heritage Month at PhRMA
October 11, 2023
Word of the Month: AMR
September 27, 2023
New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients
September 11, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
Decentralized clinical trials and the future of drug development
August 9, 2023
WTAS on reasonable pricing and public-private partnerships
August 8, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
How FDA’s modernization strategy could improve drug development
June 20, 2023
Biopharmaceutical science powered by PRIDE
June 16, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Reject efforts to undermine America’s R&D ecosystem
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Setting the record straight on accelerated approval
May 22, 2023
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
May 11, 2023
Support for continued progress is critical for pediatric drug development
May 8, 2023
New resource underscores the importance of small molecule medicines
May 4, 2023
Policies need to address the growing threat of antimicrobial resistance
April 28, 2023
World IP Day 2023: Celebrating women leaders in innovation
April 26, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
A guide to MedPAC’s Part B vote today
April 13, 2023
FDA should remain the authority on the safety and effectiveness of medicines
April 12, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
MedPAC proposal threatens access to medicines in Part B
April 6, 2023
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
March 28, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
PhRMA submits comments to OSTP on enhancing clinical trial diversity
March 21, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
Celebrating 40 years of the Orphan Drug Act on Rare Disease Day
February 28, 2023
PhRMA submits comments to USPTO highlighting important role of patent system in medicine development
February 23, 2023
State policymakers can protect American innovation and help Americans live longer, healthier lives
February 9, 2023
Recognizing National Glaucoma Awareness Month
February 1, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
WTAS: Inflation Reduction Act already impacting R&D decisions
January 17, 2023
What you should know about real-world evidence and drug development
December 19, 2022
Three things to know about the accelerated approval pathway
December 12, 2022
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
Expanding TRIPS waiver would jeopardize biopharmaceutical research and development
November 17, 2022
Congratulations to our 2022 Working for Cures Employee Champions
November 10, 2022
New government price setting policy threatens post-approval research
November 10, 2022
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
November 8, 2022
New paper: Addressing the growing crisis of mental health and substance use disorders
November 7, 2022
Protecting treatment advances for breast cancer
October 31, 2022
The law driving technology transfer and fostering innovation
October 24, 2022
Don’t take anti-innovation, activist funded academics at their word
October 18, 2022
PDUFA and BsUFA reauthorizations are wins for patients
October 5, 2022
Mental Illness Awareness Week – A time for reflection
October 3, 2022
New Report: Nearly 800 medicines in development to treat chronic conditions
September 29, 2022
Recognizing National Sickle Cell Awareness Month
September 23, 2022
Timely reauthorization of PDUFA and BsUFA is vital to the FDA’s review of medicines
September 12, 2022
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
August 16, 2022
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
August 10, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
An open letter to Congress: Stand with patients and future cures
August 4, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
August 1, 2022
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
July 29, 2022
The Senate’s latest price setting proposal will undermine: American medical innovation
July 27, 2022
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
July 18, 2022
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
July 14, 2022
Word of the Month: Biomarkers and surrogate endpoints
July 11, 2022
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
July 7, 2022
CMS coverage decision restricts access to treatments for Alzheimer’s disease
June 22, 2022
Key takeaways from ASCO's annual meeting
June 10, 2022
Biopharmaceutical researchers to discuss the value of R&D with Congress
June 9, 2022
Recognizing LGBTQ+ Pride in biopharmaceutical science
June 9, 2022
Report: More than 500 medicines in development to treat disorders of the blood
May 18, 2022
Ensuring timely reauthorization of PDUFA and BsUFA
May 11, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
Spotlighting a growing mental health challenge
May 9, 2022
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
April 28, 2022
The biopharmaceutical industry leads in helping women achieve new heights, according to IAM’s diversity 100
April 20, 2022
Report: More than 600 medicines in development for diseases affecting women
March 31, 2022
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
March 17, 2022
Biopharmaceutical industry drives economic growth in all 50 states
March 14, 2022
Biopharmaceutical research and development has ushered in a decade of innovation in rare disease
February 28, 2022
4 things to know about biopharmaceutical efforts to fight cancer
February 24, 2022
What you need to know about newly authorized COVID-19 antiviral treatments
February 22, 2022
Guest post: Joining forces to combat the COVID-19 mental health crisis
February 17, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
The importance of timely PDUFA and BsUFA reauthorization
February 3, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
Protecting U.S. innovation abroad to support economic and pandemic recovery
February 1, 2022
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
January 24, 2022
New data show continued decline in death rates for cancer patients related to treatment advances
January 20, 2022
New Report: Nearly 800 new medicines in development to treat rare diseases
December 16, 2021
Recap: Our inaugural graduate summit and career expo
December 8, 2021
New report details the promise of the biopharmaceutical pipeline
December 7, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS
December 1, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance
November 18, 2021
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy
November 1, 2021
Guest post: Continued research and development is critical for ALS patients and families
October 25, 2021
New report shows more than 260 medicines in development to fight neurodegenerative diseases
October 12, 2021
The important role of antivirals in the fight against COVID-19
October 6, 2021
Understanding Long COVID-19
September 29, 2021
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
September 28, 2021
Meeting Tomorrow: Looking ahead to PDUFA VII
September 27, 2021
PhRMA releases 2021 industry profile
September 20, 2021
Addressing data challenges to improve health equity
September 17, 2021
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
September 8, 2021
Patients and innovators lose if the government pursues ‘march-in’
September 7, 2021
The impact of monoclonal antibodies and COVID-19 recovery
September 2, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
PDUFA VII is critical for future biopharmaceutical innovation and for patients
August 23, 2021
Recognizing Hepatitis R&D on World Hepatitis Day
July 28, 2021
We Work for Health: Discovering champions, even amid challenging times
July 26, 2021
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
July 22, 2021
3 things that support robust biopharmaceutical research and development
June 29, 2021
IP Explained: How does the U.S. patent process work?
June 24, 2021
Watch: Building trust and enhancing clinical trial diversity
June 24, 2021
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
June 23, 2021
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
June 22, 2021
Researchers to shine light on biopharmaceutical R&D with policymakers
June 15, 2021
How research evolves and brings new hope to patients
June 11, 2021
Continued R&D into Alzheimer’s disease means hope for patients, families and caregivers
June 4, 2021
How strengthening the biosimilar marketplace benefits patients
May 18, 2021